Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II study of TY101 injection in advanced solid tumors and lymphoma
CTR20201111Phase 2Active
- Sponsor
- Tayu Huaxia Biotech
- Start
- Jun 2020
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of TY101 in Nonhematologic neoplasms, lymphoma, peripheral T-cell lymphoma (PTCL), sponsored by Tayu Huaxia Biotech. Started Jun 2020; status: active.
02
Drugs
TY101
03
Conditions
Nonhematologic neoplasmslymphomaperipheral T-cell lymphoma (PTCL)
Beyond the preview
Go deeper on CTR20201111.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20201111.